Kezar Life Sciences, Inc.
KZR
$3.96
-$0.04-1.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0.00 | 7.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 0.00 | 7.00M |
| Cost of Revenue | 41.86M | 48.57M | 48.57M | 55.18M | 62.68M |
| Gross Profit | -41.86M | -48.57M | -48.57M | -55.18M | -55.68M |
| SG&A Expenses | 21.72M | 22.30M | 23.39M | 23.61M | 26.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.75M | 83.05M | 89.14M | 95.96M | 106.54M |
| Operating Income | -75.75M | -83.05M | -89.14M | -95.96M | -99.54M |
| Income Before Tax | -70.79M | -78.63M | -83.74M | -95.78M | -98.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -70.79 | -78.63 | -83.74 | -95.78 | -98.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.79M | -78.63M | -83.74M | -95.78M | -98.57M |
| EBIT | -75.75M | -83.05M | -89.14M | -95.96M | -99.54M |
| EBITDA | -74.74M | -82.02M | -88.10M | -94.90M | -98.46M |
| EPS Basic | -12.46 | -13.55 | -14.26 | -13.15 | -13.55 |
| Normalized Basic EPS | -7.79 | -8.34 | -8.78 | -7.56 | -7.81 |
| EPS Diluted | -12.46 | -13.55 | -14.26 | -13.15 | -13.55 |
| Normalized Diluted EPS | -7.79 | -8.34 | -8.78 | -7.56 | -7.81 |
| Average Basic Shares Outstanding | 29.21M | 29.19M | 29.16M | 29.13M | 29.11M |
| Average Diluted Shares Outstanding | 29.21M | 29.19M | 29.16M | 29.13M | 29.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |